{"id":1107,"date":"2025-01-25T14:15:52","date_gmt":"2025-01-25T14:15:52","guid":{"rendered":"https:\/\/staging.irccs.com\/?post_type=laboratory&p=1107"},"modified":"2025-11-10T14:28:52","modified_gmt":"2025-11-10T14:28:52","slug":"cancer-molecular-biology","status":"publish","type":"laboratory","link":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/","title":{"rendered":"CANCER MOLECULAR BIOLOGY"},"content":{"rendered":"\n

<\/span>Research topic<\/strong><\/h2>\n\n\n\n

Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer.<\/p>\n\n\n\n

<\/span>Background<\/strong><\/h2>\n\n\n\n

Gastric cancer (GC) is the world’s third leading cause of cancer mortality. In spite of significant therapeutic advances, the overall clinical outcome for patients with advanced GC is poor, with median survival of less than 1 year. In spite of whole genome molecular profiling which shed light on the genetic landscape of this tumor, at present few targeted therapies are licenced to treat GC.<\/p>\n\n\n\n

<\/span>Achievements<\/strong><\/h2>\n\n\n\n

We generated a platform of around 300 patient-derived xenografts (PDXs) that recapitulate the heterogeneity of this disease; at present, this is the widest gastric cancer PDX platform in an academic institution in the world. We also set up a collection of gastric cancer primary cell lines and organoids. Taking advantage of this platform we have achieved several goals: i) we have identified the MET oncogene as a target in gastric cancer patients in which this gene is amplified; ii) we reported the clinical activity of EGFR monoclonal antibodies (mAb) in patients bearing a high level (>8 copies) of EGFR gene amplification, and showed that in patient-derived xenografts, the combination of an EGFR mAb and a tyrosine kinase inhibitor is significantly more effective and long lasting than mAb monotherapy; iii) In preclinical randomized trials we have shown that in HER2-driven gastric tumors, a boosted HER2 therapeutic blockade (association of Trastuzumab\/Pertuzumab or of Trastuzumab and Lapatinib) is required for optimal efficacy, leading to complete and durable responses in most of the cases. Our results thus suggest that a selected subpopulation of HER2-\u201chyper\u201d-amplifed GC patients could strongly benefit from this strategy; iv) we have demonstrated that PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended; v) we have generated mouse models of gastric cancer bearing microsatellite instability to reveal the evolution of this subtype of tumor; vi) we have identified and characterized gastric cancer \u201cpersister cells\u201d, responsible for tumor relapse.<\/p>\n\n\n\n

<\/span>Conclusions and perspectives<\/strong><\/h2>\n\n\n\n

Since gastric cancer is a very common disease worldwide, the identification of novel \u2018druggable\u2019 and validated targets would be extremely important from a clinical point of view, even if their prevalence is very low. Our results lay the foundations for a focused design of clinical trials aimed at the effective treatment of a fraction of GC patients with drugs targeting molecular alterations identified as oncogenic drivers.  <\/p>\n\n\n\n

<\/span>Publications<\/h2>\n\n\n\n

At this link<\/a><\/strong>, you can find all the scientific publications of the Principal Investigator.<\/p>\n\n\n\t

\n\t\t\n
\n\t
\n\t\t\t\t\t

Selected Publications<\/h2>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\tBRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t

Petrelli A, Rizzolio S, Pietrantonio F, Bellomo SE, Benelli M, De Cecco L, Romagnoli D, Berrino E, Orr\u00f9 C, Ribisi S, Moya-Rull D, Migliore C, Conticelli D, Maina IM, Puliga E, Serra V, Pellegrino B, Llop-Guevara A, Musolino A, Siena S, Sartore-Bianchi A, Prisciandaro M, Morano F, Antista M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GL, Amisano MF, Ferrero A, Marchi\u00f2 C, Corso S, Giordano S. Cancer Res. 2023; 83:1699-1710. doi: 10.1158\/0008-5472.CAN-22-2620. PMID: 37129948<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tHER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t

Pietrantonio F, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, Morano F, Migliore C, Niger M, Castagnoli L, Pupa SM, Marchi\u00f2 C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S. Clin Cancer Res. 2023 Feb 1;29(3):571-580. doi: 10.1158\/1078-0432.CCR-22-2533. PMID: 36413222\r\n<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tPersonalized therapeutic strategies in HER2-driven gastric cancer.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t

Ughetto S, Migliore C, Pietrantonio F, Apicella M, Petrelli A, D’Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capel\u00f4a T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, Morano F, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchi\u00f2 C, Cassoni P, Guarrera S, Corso S, Giordano S. Gastric Cancer. 2021 Jul;24(4):897-912. doi: 10.1007\/s10120-021-01165-w. PMID: 33755862\r\n<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tOptimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t

Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D’Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, De Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchi\u00f2 C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S. Clin Cancer Res. 2021; 27:3126-3140. doi: 10.1158\/1078-0432.CCR-20-0121..PMID: 33542076\r\n<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\tReflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t

Lu H, Cao LL, Ballout F, Belkhiri A, Peng D, Chen L, Chen Z, Soutto M, Wang TC, Que J, Giordano S, Washington MK, Chen S, McDonald OG, Zaika A, El-Rifai W. Gut. 2023. doi: 10.1136\/gutjnl-2023-329455. Online ahead of print. PMID: 37734913\r\n<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true,"footnotes":""},"class_list":["post-1107","laboratory","type-laboratory","status-publish","hentry"],"acf":[],"yoast_head":"\nCANCER MOLECULAR BIOLOGY - Istituto di Candiolo<\/title>\n<meta name=\"description\" content=\"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CANCER MOLECULAR BIOLOGY - Istituto di Candiolo\" \/>\n<meta property=\"og:description\" content=\"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/\" \/>\n<meta property=\"og:site_name\" content=\"Istituto di Candiolo\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/istitutodicandiolo\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T14:28:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@fpoirccs\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/\",\"url\":\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/\",\"name\":\"CANCER MOLECULAR BIOLOGY - Istituto di Candiolo\",\"isPartOf\":{\"@id\":\"https:\/\/irccs.com\/it\/#website\"},\"datePublished\":\"2025-01-25T14:15:52+00:00\",\"dateModified\":\"2025-11-10T14:28:52+00:00\",\"description\":\"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the\",\"breadcrumb\":{\"@id\":\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irccs.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CANCER MOLECULAR BIOLOGY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irccs.com\/it\/#website\",\"url\":\"https:\/\/irccs.com\/it\/\",\"name\":\"INOC\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irccs.com\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CANCER MOLECULAR BIOLOGY - Istituto di Candiolo","description":"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/","og_locale":"it_IT","og_type":"article","og_title":"CANCER MOLECULAR BIOLOGY - Istituto di Candiolo","og_description":"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the","og_url":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/","og_site_name":"Istituto di Candiolo","article_publisher":"https:\/\/www.facebook.com\/istitutodicandiolo\/","article_modified_time":"2025-11-10T14:28:52+00:00","twitter_card":"summary_large_image","twitter_site":"@fpoirccs","twitter_misc":{"Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/","url":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/","name":"CANCER MOLECULAR BIOLOGY - Istituto di Candiolo","isPartOf":{"@id":"https:\/\/irccs.com\/it\/#website"},"datePublished":"2025-01-25T14:15:52+00:00","dateModified":"2025-11-10T14:28:52+00:00","description":"Research topic Our group aims to identify and validate novel targets and therapeutic strategies in gastric cancer. Background Gastric cancer (GC) is the","breadcrumb":{"@id":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irccs.com\/it\/laboratori\/cancer-molecular-biology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irccs.com\/it\/"},{"@type":"ListItem","position":2,"name":"CANCER MOLECULAR BIOLOGY"}]},{"@type":"WebSite","@id":"https:\/\/irccs.com\/it\/#website","url":"https:\/\/irccs.com\/it\/","name":"INOC","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irccs.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"_links":{"self":[{"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/laboratory\/1107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/laboratory"}],"about":[{"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/types\/laboratory"}],"version-history":[{"count":1,"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/laboratory\/1107\/revisions"}],"predecessor-version":[{"id":2866,"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/laboratory\/1107\/revisions\/2866"}],"wp:attachment":[{"href":"https:\/\/irccs.com\/it\/wp-json\/wp\/v2\/media?parent=1107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}